TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Saturday, May 30, 2026 1 min read
Key Takeaway: The TRIDENT study investigates the efficacy of relacorilant combined with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma. Presented at the American Society of Clinical Oncology Annual Meeting, the study aims to provide insights into new treatment options for this challenging cancer type.
Price reaction · baseline $69.49 (2026-05-29 close) · 1 other CORT headline(s) in the window, move may be shared
day 0 close · peak
+1.4%
Market Sentiment Analysis
POSITIVE FACTORS
The study focuses on a novel combination therapy for pancreatic cancer.
Relacorilant shows potential in treating chemotherapy-naïve patients.
The presentation at a major conference highlights its significance.
Full Press Release Details
Presented : American Society of Clinical Oncology Annual Meeting , 30 May 2026, Chicago, IL
Presenter : Erkut H. Borazanci , MD, MS
Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.
Download Poster
The post TRIDENT: A Phase 2 Study of Relacorilant Plus Nab-paclitaxel and Gemcitabine in Chemotherapy-naïve Patients With Metastatic Pancreatic Ductal Adenocarcinoma appeared first on Corcept Therapeutics .
Frequently Asked Questions
What is the TRIDENT study about?
The TRIDENT study examines relacorilant combined with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma.
Where was the TRIDENT study presented?
The study was presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.
Who presented the TRIDENT study?
Dr. Erkut H. Borazanci, MD, MS, presented the TRIDENT study.
What type of patients were involved in the TRIDENT study?
The study involved chemotherapy-naïve patients with metastatic pancreatic ductal adenocarcinoma.